Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Soverini S, Martelli M, Bavaro L, De Benedittis C, Papayannidis C, Sartor C, Sorà F, Albano F, Galimberti S, Abruzzese E, Annunziata M, Russo S, Stulle M, Imovilli A, Bonifacio M, Maino E, Stagno F, Maria Basilico C, Borlenghi E, Fozza C, Mignone F, Minari R, Stella S, Baccarani M, Cavo M, Martinelli G. Soverini S, et al. Among authors: imovilli a. Br J Haematol. 2021 Apr;193(2):271-279. doi: 10.1111/bjh.17301. Epub 2021 Jan 6. Br J Haematol. 2021. PMID: 33403687
Rearrangements of ATP5L-KMT2A in acute lymphoblastic leukaemia.
Ferrari A, Ghelli Luserna Di Rora A, Domizio C, Papayannidis C, Simonetti G, Maria Hernández-Rivas J, Rondoni M, Giglio F, Abruzzese E, Imovilli A, Iacobucci I, Calistri D, Martinelli G. Ferrari A, et al. Among authors: imovilli a. Br J Haematol. 2021 Mar;192(6):e139-e144. doi: 10.1111/bjh.17265. Epub 2020 Dec 13. Br J Haematol. 2021. PMID: 33314053 Free article. Clinical Trial. No abstract available.
Incidence, treatment and outcome of central nervous system relapse in adult acute lymphoblastic leukaemia patients treated front-line with paediatric-inspired regimens: A retrospective multicentre Campus ALL study.
Dargenio M, Bonifacio M, Chiaretti S, Vitale A, Fracchiolla NS, Papayannidis C, Giglio F, Salutari P, Audisio E, Scappini B, Zappasodi P, Defina M, Forghieri F, Scattolin AM, Todisco E, Lunghi M, Guolo F, Del Principe MI, Annunziata M, Lazzarotto D, Cedrone M, Pasciolla C, Imovilli A, Tanasi I, Trappolini S, Cerrano M, La Starza R, Krampera M, Di Renzo N, Candoni A, Pizzolo G, Ferrara F, Foà R. Dargenio M, et al. Among authors: imovilli a. Br J Haematol. 2023 Feb;200(4):440-450. doi: 10.1111/bjh.18537. Epub 2022 Nov 6. Br J Haematol. 2023. PMID: 36335916 Free PMC article.
Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study.
Fracchiolla NS, Sciumè M, Papayannidis C, Vitale A, Chiaretti S, Annunziata M, Giglio F, Salutari P, Forghieri F, Lazzarotto D, Lunghi M, Imovilli A, Scappini B, Bonifacio M, Dargenio M, Gurrieri C, Todisco E, Defina M, Del Principe MI, Zappasodi P, Cerrano M, Santoro L, Tagliaferri E, Barozzi E, De Roberto P, Canzi M, Buzzatti E, Sartor C, Passamonti F, Foà R, Curti A. Fracchiolla NS, et al. Among authors: imovilli a. Cancers (Basel). 2023 Sep 19;15(18):4623. doi: 10.3390/cancers15184623. Cancers (Basel). 2023. PMID: 37760592 Free PMC article.
Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells.
Ghelli Luserna Di Rorà A, Ghetti M, Ledda L, Ferrari A, Bocconcelli M, Padella A, Napolitano R, Fontana MC, Liverani C, Imbrogno E, Bochicchio MT, Paganelli M, Robustelli V, Sanogo S, Cerchione C, Fumagalli M, Rondoni M, Imovilli A, Musuraca G, Martinelli G, Simonetti G. Ghelli Luserna Di Rorà A, et al. Among authors: imovilli a. Cell Biol Toxicol. 2023 Jun;39(3):795-811. doi: 10.1007/s10565-021-09640-x. Epub 2021 Sep 14. Cell Biol Toxicol. 2023. PMID: 34519926 Free PMC article.
10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial.
Lübbert M, Wijermans PW, Kicinski M, Chantepie S, Van der Velden WJFM, Noppeney R, Griškevičius L, Neubauer A, Crysandt M, Vrhovac R, Luppi M, Fuhrmann S, Audisio E, Candoni A, Legrand O, Foà R, Gaidano G, van Lammeren-Venema D, Posthuma EFM, Hoogendoorn M, Giraut A, Stevens-Kroef M, Jansen JH, de Graaf AO, Efficace F, Ammatuna E, Vilque JP, Wäsch R, Becker H, Blijlevens N, Dührsen U, Baron F, Suciu S, Amadori S, Venditti A, Huls G; EORTC Leukemia Group, GIMEMA, and German MDS Study Group. Lübbert M, et al. Lancet Haematol. 2023 Nov;10(11):e879-e889. doi: 10.1016/S2352-3026(23)00273-9. Lancet Haematol. 2023. PMID: 37914482 Free article. Clinical Trial.
Characterization of specific immune responses to different Aspergillus antigens during the course of invasive Aspergillosis in hematologic patients.
Potenza L, Vallerini D, Barozzi P, Riva G, Forghieri F, Beauvais A, Beau R, Candoni A, Maertens J, Rossi G, Morselli M, Zanetti E, Quadrelli C, Codeluppi M, Guaraldi G, Pagano L, Caira M, Del Giovane C, Maccaferri M, Stefani A, Morandi U, Tazzioli G, Girardis M, Delia M, Specchia G, Longo G, Marasca R, Narni F, Merli F, Imovilli A, Apolone G, Carvalho A, Comoli P, Romani L, Latgè JP, Luppi M. Potenza L, et al. Among authors: imovilli a. PLoS One. 2013 Sep 4;8(9):e74326. doi: 10.1371/journal.pone.0074326. eCollection 2013. PLoS One. 2013. PMID: 24023936 Free PMC article.
14 results